DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
AstraZeneca advances scientific leadership in haematology at ASH 2023
Calquence six-year follow-up data reinforce long-term benefit in chronic lymphocytic
leukaemia, and data across multiple haematology assets showcase breadth of
promising early pipeline
New, longer-term data from ALPHA Phase III trial will further show potential of
danicopan to address clinically significant extravascular haemolysis and maintain
disease control, allowing paroxysmal nocturnal haemoglobinuria patients to continue
standard-of-care treatment with Ultomiris or Soliris
AstraZeneca will present new clinical and real-world data in multiple haematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
A total of 63 abstracts will feature 14 approved and potential new medicines across the Company’s portfolio and pipeline including from Alexion, AstraZeneca’s Rare Disease group, in chronic lymphocytic leukaemia (CLL) and several types of lymphoma, paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS) and amyloid light-chain (AL) amyloidosis.
Anas Younes, Senior Vice President, Haematology R&D, AstraZeneca, said: “Our data at ASH will exemplify how we are advancing a range of innovative modalities including antibody drug conjugates, next-generation immunotherapies and T-cell engagers in haematology. Updated clinical data for AZD0486, our CD19/CD3 T-cell engager, reinforce our belief in this approach as a potential new treatment for lymphoma, and new Calquence data continue to demonstrate long-term efficacy and safety in chronic lymphocytic leukaemia with further follow up.”
Gianluca Pirozzi, Senior Vice President, Head of Development, Regulatory and Safety, Alexion, said: “Alexion has transformed the treatment landscape and redefined care for the paroxysmal nocturnal haemoglobinuria patient community over the past two decades. At the ASH Annual Meeting, new results from our pivotal ALPHA trial will demonstrate the promise of Factor D inhibition to advance care for the small subset of patients with paroxysmal nocturnal haemoglobinuria who experience clinically significant extravascular haemolysis. We are proud to further our leadership in rare disease by sharing data from our robust haematology pipeline, reflecting our commitment to innovation and improving outcomes for the patients and families we serve.”
Calquence continues to demonstrate long-term benefits in CLL
Six-year follow-up data from the pivotal ELEVATE-TN Phase III trial will further support the continued efficacy, safety and tolerability of Calquence for long-term use in patients with treatment-naïve CLL.1
Data from a Phase II trial will show the safety and efficacy of Calquence and rituximab followed by chemotherapy and autologous stem cell transplantation in fit patients with treatment-naïve mantle cell lymphoma (MCL).2
An analysis of five prospective Calquence trials, including three randomised, controlled Phase III trials and two non-randomised trials, will show acceptable safety outcomes based on rates of nonfatal and fatal ventricular arrhythmias and sudden death in patients with CLL.3
Novel early assets show potential to improve outcomes for blood cancer patients
Data from our early portfolio will demonstrate how the Company is advancing multiple modalities across several scientific platforms, including Immuno-Oncology, Immune-Engagers, Antibody Drug Conjugates (ADCs) and Epigenetics as part of its strategy to attack cancer from multiple angles.
Updated Phase I data for AstraZeneca’s CD19/CD3 T-cell engager, AZD0486, will further demonstrate the acceptable safety profile and high response rate of this treatment in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).4 We will also present the first clinical data on sabestomig, a PD-1/TIM-3 targeting bispecific antibody, in R/R Hodgkin lymphoma, showing encouraging early signals of activity.5
The first preclinical data for AZD9829, a novel CD123-targeting ADC, using AstraZeneca’s proprietary linker technology to deliver a topoisomerase I inhibitor warhead, will demonstrate promising anti-tumour activity in acute myeloid leukaemia.6 In addition, preclinical data will demonstrate anti-tumour activity of AstraZeneca’s novel PRMT5 inhibitor in MTAP silenced Hodgkin lymphoma models.7
Showcasing advances to bolster our leadership in PNH with new data on Factor D inhibition and impact of C5 inhibition in long-term disease control
New results from the 24-week and long-term extension period from the pivotal ALPHA Phase III trial will reinforce the potential for danicopan add-on therapy to address clinically significant extravascular haemolysis (EVH) in the small subset of PNH patients who experience this condition while treated with C5 inhibitor therapy, allowing them to maintain control of intravascular haemolysis (IVH) through standard-of-care treatment with Ultomiris (ravulizumab) or Soliris (eculizumab).8
Further, patient-reported outcomes from the ALPHA trial will suggest danicopan as an add-on to Ultomiris or Soliris improved quality of life compared to C5 inhibitor therapy alone in patients with PNH who experience clinically significant EVH.9
Additionally, Alexion will present an analysis of six-year outcomes from the Phase III clinical trial evaluating the safety and efficacy of Ultomiris in patients with PNH who did not have previous treatment with a C5 inhibitor.10 The analysis compared survival against untreated patients in the International PNH Registry, the largest global real-world database of patients with PNH. Results will suggest Ultomiris improved survival and maintained effective long-term control of IVH, the most significant contributor to morbidity and premature mortality in PNH.10
![AstraZeneca Advances Scientific Leadership In Haematology At ASH 2023 AstraZeneca Advances Scientific Leadership In Haematology At ASH 2023](https://www.oneamyloidosisvoice.com/wp-content/uploads/2022/06/AstraZeneca-Logo.jpg )
![](https://www.oneamyloidosisvoice.com/application/themes/onevoice-child/images/bookmark.png)
Related Content
-
educationAL Amyloidosis and FatigueFatigue is a feeling of near constant ex...
-
people & placesHans Lee, MDHans Lee is an Assistant Professor in th...
-
people & placesRobert A. Vescio, MDRobert A. Vescio is a medical director a...
-
people & placesSaulius K. Girnius, MDDr. Saulius Girnius is a hematologist ...
-
educationRecent Advances in Diagnosis and Treatment of Cardiac AmyloidosisCardiac amyloidosis (CA) has been believ...
-
people & placesJason Valent, MDJason Valent is a Hematologist/Oncologis...
-
people & placesScott C Feitell, DODr. Feitell specializes in Advanced Hear...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Reset password
Enter Phone Number
password changed successfully!
![oneAMYLOIDOSISvoice oneAMYLOIDOSISvoice](https://www.oneamyloidosisvoice.com/application/themes/onevoice-child/images/logo-desktop.gif)
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
![oneAMYLOIDOSISvoice oneAMYLOIDOSISvoice](https://www.oneamyloidosisvoice.com/application/themes/onevoice-child/images/logo-desktop.gif)
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
password reset email sent
![oneAMYLOIDOSISvoice oneAMYLOIDOSISvoice](https://www.oneamyloidosisvoice.com/application/themes/onevoice-child/images/logo-desktop.gif)
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
![oneAMYLOIDOSISvoice oneAMYLOIDOSISvoice](https://www.oneamyloidosisvoice.com/application/themes/onevoice-child/images/oneamyloidosisvoice.png)
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
![oneAMYLOIDOSISvoice oneAMYLOIDOSISvoice](https://www.oneamyloidosisvoice.com/application/themes/onevoice-child/images/logo-desktop.gif)
This feature is only available to oneAMYLOIDOSISvoice members.
Register
This feature is only available to oneAMYLOIDOSISvoice members.
Log in
you haven't confirmed your email address yet. resend confirmation email
Want to find the info you need faster?
The symptoms of Amyloidosis and the treatments that are available vary depending on which type of Amyloidosis a patient has been diagnosed with. Select which type you want to learn more about, and oneAMYLOIDOSISvoice can highlight the resources that are most relevant to your MPS/ML type.
Not now